These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25361808)

  • 1. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
    Venook AP; Arcila ME; Benson AB; Berry DA; Camidge DR; Carlson RW; Choueiri TK; Guild V; Kalemkerian GP; Kurzrock R; Lovly CM; McKee AE; Morgan RJ; Olszanski AJ; Redman MW; Stearns V; McClure J; Birkeland ML
    J Natl Compr Canc Netw; 2014 Nov; 12(11):1629-49. PubMed ID: 25361808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision oncology: A new era of cancer clinical trials.
    Renfro LA; An MW; Mandrekar SJ
    Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.
    Berry DA; Herbst RS; Rubin EH
    Clin Cancer Res; 2012 Feb; 18(3):638-44. PubMed ID: 22298897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research.
    Lai TL; Liao OY; Kim DW
    Contemp Clin Trials; 2013 Nov; 36(2):651-63. PubMed ID: 23994669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definitions and statistical properties of master protocols for personalized medicine in oncology.
    Renfro LA; Mandrekar SJ
    J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine clinical trials: defining new treatment strategies.
    Heckman-Stoddard BM; Smith JJ
    Semin Oncol Nurs; 2014 May; 30(2):109-16. PubMed ID: 24794084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing cancer drug development through precision medicine and innovative designs.
    Zhang W; Wang J; Menon S
    J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.
    Heerspink HJL; List J; Perkovic V
    Diabetes Obes Metab; 2018 Oct; 20 Suppl 3(Suppl Suppl 3):14-18. PubMed ID: 30294954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
    Lin JA; He P
    Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of molecular profiling in clinical trials for advanced metastatic cancers.
    Kummar S; Williams PM; Lih CJ; Polley EC; Chen AP; Rubinstein LV; Zhao Y; Simon RM; Conley BA; Doroshow JH
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological and practical challenges for personalized cancer therapies.
    Wistuba II; Gelovani JG; Jacoby JJ; Davis SE; Herbst RS
    Nat Rev Clin Oncol; 2011 Mar; 8(3):135-41. PubMed ID: 21364686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
    Farwell MD; Clark AS; Mankoff DA
    JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenges in the clinical implementation of precision medicine companion diagnostics.
    Keeling P; Clark J; Finucane S
    Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial designs incorporating predictive biomarkers.
    Renfro LA; Mallick H; An MW; Sargent DJ; Mandrekar SJ
    Cancer Treat Rev; 2016 Feb; 43():74-82. PubMed ID: 26827695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.